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Abstract
Background: Virtual Histology Intravascular Ultrasound (VH–IVUS) may be used to detect early signs of unstable
coronary artery disease. Monocyte Chemoattractant Protein-1 (MCP-1) is linked with coronary atherosclerosis and
plaque instability and could potentially be modified by folic acid treatment.
Methods: In a randomized, prospective study, 102 patients with stable angina pectoris (SAP) received percutaneous
coronary intervention and established medical treatment as well as either homocysteine-lowering folic acid/vitamin
B12 (±B6) or placebo (±B6) for 1 year before VH–IVUS was performed. The presence of VH-Thin-Cap Fibroatheroma
(VH-TCFA) in non-intervened coronary vessels was registered and serum levels of MCP-1 were measured. The
patients were subsequently followed for incident myocardial infarction (MI).
Results: Patients treated with folic acid/vitamin B12 had a geometric mean (SD) MCP-1 level of 79.95 (1.49) versus
86.00 (1.43) pg/mL for patients receiving placebo (p-value 0.34). VH-TCFA lesions were present in 7.8% of patients
and did not differ between intervention arms (p-value 0.47). Serum levels of MCP-1 were 1.46 (95% CI 1.12 to 1.92)
times higher in patients with VH-TCFA lesions than in those without (p-value 0.005). Afterwards, patients were
followed for median 2.1 years and 3.8% experienced a myocardial infarction (MI), which in post-hoc Cox regression
analyses was independently predicted by both MCP-1 (P-value 0.006) and VH-TCFA (p-value 0.01).
Conclusions: In patients with SAP receiving established medical treatment, folic acid supplementation is not
associated with either presence of VH-TCFA or levels of MCP-1. MCP-1 is however associated with VH-TCFA, a
finding corroborated by increased risk for future MI.
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Introduction
While significant progress has been made in both diagnosis
and treatment of coronary artery disease (CAD), a substantial
number of patients still experience recurrent coronary events
[1]. Common underlying features of these events are non-flow-
limiting, angiographically non-significant stenosis – culprit
lesions with an unstable atherosclerotic plaque phenotype.
Morphologically, these lesions are characterized by: a thin cap
fibrous atheroma (TCFA) overlying a necrotic core with an
extensive inflammatory infiltrate, a plaque erosion or a calcified
nodule [2-4]. In recent years, it has been increasingly apparent
that such lesions are not satisfactorily diagnosed in clinical
practice, and there is a growing agreement that early detection
and intensive treatment of vulnerable lesions are paramount in
order to decrease the rate of coronary events in patients with
medically treated stable angina pectoris (SAP) [5].
One well-developed technology applicable for this setting is
spectral analysis of intravascular ultrasound (IVUS) radio
frequency data [6] called Virtual Histology IVUS (VH-IVUS).
Using VH–IVUS one can identify VH-Thin-Cap Fibroatheroma
(VH-TCFA). VH-TCFA has been reported to predict clinical
events in prospective studies [7] and identification of patients
at-risk is feasible if one could identify occult VH-TCFA lesion.
The recognition of the inflammatory response as playing a
pivotal role in the formation and progression of atherosclerosis
has been one of the leading breakthroughs in recent years [8].
High-sensitivity C-reactive protein (hsCRP) has already earned
its mark as an independent risk factor [9] and several other
inflammatory markers have been proposed. Nevertheless,
despite optimal pharmacological treatment and
revascularization, a sub-group of patients continue to
experience cardiovascular events that are thought to be the
end-point of an inflammatory process not adequately controlled
by conventional treatment.
Monocyte Chemoattractant Protein-1 (MCP-1), also known
as Chemokine ligand [C-C motif] 2 (CCL2), is an extensively
studied chemokine involved in the recruitment of monocytes,
dendritic cells and Th-cells [10] and has been associated to
macrophage activity in atherosclerotic plaques [11-13].
Hyperhomocysteinemia has been linked with elevated MCP-1
[14] and it has been shown that folic acid supplementation
lowers the levels of MCP-1 in hyperhomocysteinemic rats [15].
Interestingly, studies in humans have shown that folic acid
supplementation lowers levels of MCP-1 in obese patients [16].
In children with low body mass index (BMI) there is a negative
correlation between MCP-1 and plasma homocysteine which is
not present in obese children [17].
Hyperhomocysteinemia has been associated with
cardiovascular disease in several prospective studies [18] and
numerous explanatory pathomechanisms have been proposed
[19-21]. Treatment with B-vitamins, including folic acid and
vitamin B12, has been shown to lower plasma homocysteine by
supplying methyl groups for remethylation of homocysteine.
More than 20 years of homocysteine studies have culminated
in several large scale clinical intervention trials that have shown
no effect on cardiovascular mortality from homocysteine-
lowering folic acid supplementation [20,22-26].
The goal of the current study was to explore the effect of folic
acid supplementation on the levels of MCP-1 and presence of
VH-TCFA in a cohort of patients with established CAD and
optimally treated SAP and further to investigate the relationship
between MCP-1 and VH-TCFA.
Methods
Study design and patient population
This trial was a sub-study of the Western Norway B-vitamin
Intervention Trial (WENBIT) in collaboration with the Global
Virtual Histology Intravascular Ultrasound (VH–IVUS) Registry.
WENBIT investigated the effect of homocysteine-lowering B-
vitamin supplementation on cardiovascular end-points as
secondary prevention in a non-fortified population. The patients
were randomized and given B-vitamin supplementation
according to a 2x2 factorial design previously described [27];
receiving an oral capsule with one of the following
compositions: folic acid 0.8 mg plus vitamin B12
(cyanocobalamin) 0.4 mg with or without vitamin B6
(pyridoxine) 40 mg or vitamin B6 alone or placebo (defined as
WENBIT-baseline).
The current cohort of 105 patients was mostly recruited at
the one-year follow-up visit at Haukeland University Hospital in
Bergen, Norway (defined as VH–IVUS study inclusion, median
[IQR] 385 [399] days after WENBIT-baseline). All study
participants were recruited from a subset of patients who after
percutaneous coronary intervention (PCI) at WENBIT-baseline
had been scheduled for a repeat angiography after one year.
Accordingly, all patients had CAD and had been treated with
established medication as well as B-vitamins or placebo for at
least one year at the time of VH–IVUS study inclusion. This
recruitment took place from June 2004 to September 2005 and
is illustrated by a flow-chart in Figure 1.
IVUS-measurements were performed by the same
interventional cardiologist after intracoronary administration of
nitroglycerin 0.2 mg. A 20 MHz, 2.9Fr IVUS catheter (Eagle
Eye, Volcano Corp., Rancho Cordova, California) was
advanced to the middle or distal segment (depending on
coronary anatomy) of the selected study vessels and a
motorized pullback (0.5 mm/s) was performed until the
proximal arterial ostium. A study vessel was defined as non-
intervened, proximal segments of PCI treated study vessels or
a non-obstructive coronary study vessel technically accessible
for IVUS-measurements (belonging to the left anterior
descending artery, right coronary artery or circumflex artery) as
previously specified [28].
VH–IVUS data was lost in three patients due to corrupted
data on disc, i.e. 102 patients had complete VH–IVUS data.
Ethics statement
All clinical investigation was conducted according to the
principles expressed in the Declaration of Helsinki. Written
informed consent was obtained from all WENBIT participants,
and an additional written informed consent was collected from
patients included in the current VH–IVUS sub-study. Both
WENBIT and the current sub-study were approved by the
Regional Committee for Medical and Health Research Ethics
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(Regional Ethics Committee [REC] West/Regional Etisk Komité
[REK] vest, which is the institutional review board available at
http://helseforskning.etikkom.no), the Norwegian Medicines
Agency (Legemiddelverket) and by the Data Inspectorate
(Datatilsynet). WENBIT was registered with ClinicalTrials.gov
with identifier NCT00354081 and URL http://
www.clinicaltrials.gov/ct2/show/NCT00354081. WENBIT was a
two-centre study conducted at Haukeland University Hospital,
Bergen, and Stavanger University Hospital, Stavanger, both
located in western Norway. All clinical research was conducted
in Norway and was subject to Norwegian law.
IVUS, VH-imaging and end-point definition
All IVUS-data were transferred to the Global VH–IVUS
Registry Cardialysis, BV core lab for analyses using the pcVH
2.2 software (Volcano corp., Brussels, Belgium). This is a
validated method for visualizing plaque morphology in vivo.
IVUS-VH renders four different histological tissue components,
namely fibrous, fibro-fatty, necrotic core and calcified, all with
high correlation with histopathology in ex vivo validation studies
[3,6,29]. Each of these neointimal components where
presented as total volume (mm3) and percentage volume of
total plaque volume. An IVUS-lesion is present when the
plaque burden (plaque volume / external elastic membrane
Figure 1.  Flow-chart of patient inclusion.  The chart shows the flow of patients from the WENBIT-trial (n=3090) to inclusion in the
current IVUS-VH study (n=105). All patients were randomized to B-vitamin treatment at WENBIT-baseline. Of the 1359 patients who
had PCI at WENBIT-baseline, 371 had new, scheduled angiography at the WENBIT-one year follow-up. Of these 371 patients, 231
had received IVUS in a non-intervened vessel. IVUS-VH analysis and MCP-1 measurements were performed on 102 of these 231
patients and constituted our current study population. MCP-1 measurements were performed both at WENBIT-baseline (B-vitamin
randomization) and at IVUS-VH study inclusion. Abbreviations are FA, folic acid (0.8 mg); B12, vitamin B12 (0.4 mg); B6, vitamin B6
(40 mg); WENBIT, Western Norway B-vitamin Intervention Trial; IVUS, intravascular ultrasound; IVUS-VH, intravascular ultrasound
– virtual histology; PCI, Percutaneous coronary intervention and MCP-1, monocyte chemoattractant protein-1.
doi: 10.1371/journal.pone.0070101.g001
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volume) exceeds 40% over three consecutive frames. A VH-
TCFA lesion was present when a necrotic core rich (>10% of
cross-sectional area) element was identified in at least 3
consecutive frames with an arch of necrotic core in contact with
the lumen for at least 36° of the circumference, as per
standardized IVUS image acquisition [30]. While pull-back was
done in a per-vessel manner, data from the core lab was
provided in a per-lesion form. For subsequent analyses lesion-
level data was compressed to and presented as patient-level
data (i.e. VH-TCFA is presented as VH-TCFA per patient and
not per coronary lesion).
Clinical WENBIT end-of-study follow-up
Patients were followed from VH–IVUS study inclusion for
median (range) 734 (42–920) days (defined as WENBIT end-
of-study visit). The follow-up endpoint was defined as a
composite of fatal and non-fatal MI. All events were adjudicated
by the WENBIT-committee, unbeknownst of the MCP-1 serum
levels and VH-TCFA status of the patient.
Blood samples
Blood samples were collected at study visits. Routine blood
analyses such as hematologic parameters, renal function
markers and lipid-related factors were analyzed in fresh
samples at the Laboratory of Clinical Biochemistry, Haukeland
University Hospital, by standard methods. Blood samples for
measurements of MCP-1 were analyzed at the Institute of
Medicine in collaboration with the Lipid Group, University of
Bergen, Norway using BioPlex® 200 multiplex array (Bio-Rad
Laboratories, Hercules, CA, US). Blood samples for
measurements of B-vitamins and total homocysteine (tHcy)
were analyzed at the laboratory of Bevital AS (www.bevital.no),
Bergen, Norway.
Statistical analysis
All analyses was done using the R software version
2.12-15.1 [31]. Figures were made using the R package
ggplot2, version 0.8.3.Variables are presented as either mean
(±SD) or median (interquartile range) for continuous variables
and count (%) for categorical variables. Differences in clinical
and biochemical characteristics at WENBIT-baseline and VH–
IVUS study inclusion between intervention groups or VH-TCFA
groups were analyzed with Welch two-sample t-test or chi-
square/Fisher’s exact test with minimum likelihood where
appropriate. Change in MCP-1 levels from WENBIT-baseline to
VH–IVUS study inclusion for the whole group was done using
Welch two-sample t-test of log-transformed data. Geometric
mean and SD are presented. The effect of folic acid
supplementation levels on MCP-1, measured at both WENBIT-
baseline and VH–IVUS study inclusion, was evaluated with
Welch two-sample t-test as well as with a multivariate
generalized additive model (GAM) adjusted for age, gender,
BMI, creatinine, C-reactive protein, apolipoprotein B100, total
homocysteine, systolic blood pressure, diabetes, smoking and
statin use. The association of VH-TCFA presence and folic acid
supplementation was analyzed with Fisher’s exact test with
minimum likelihood as well as an extended generalized
additive model adjusting for age, gender, BMI, creatinine, C-
reactive protein, apolipoprotein B100, tHcy, systolic blood
pressure, diabetes, smoking and statin use. For skewed
variables we applied logarithmic transformation in order to
approximate normal distribution except for GAM analyses.
Back-transformation was applied for data presentation.
A post-hoc, hypothesis-generating evaluation of the putative
prognostic effect of VH-TCFA on ensuing risk of myocardial
infarction (MI) during subsequent follow-up as well as
relationship of VH-TCFA with MCP-1 was done. Association
between MCP-1 levels and MI was analyzed by chi-square test
and multivariate logistic regression adjusting for age, gender,
smoking status, diabetes, systolic blood pressure, BMI, hsCRP
and apolipoprotein B-100. Time to MI was evaluated using
additive Cox Proportional Hazard models. MCP-1 at VH–IVUS
study inclusion was entered as continuous variable in crude,
exploratory analyses. Multivariate models included adjustment
for age, gender, hypertension, smoking status, diabetes
mellitus, creatinine, hsCRP and apolipoprotein B-100.
Multiple imputation using a bootstrapping-based algorithm
[32] was applied to deal with missing data. Missing data
included apolipoprotein A-1, apolipoprotein B-100, systolic and
diastolic blood pressure, all n=1, but not from the same patient.
A two-sided p-value of < 0.05 was considered statistically
significant.
Results
Patient characteristics
Clinical characteristics at the time of randomization for folic
acid/vitamin B12 treatment at WENBIT-baseline is shown in
table 1. Of the 105 patients, 55 (53.9%) received folic acid and
vitamin B12 intervention, with or without vitamin B6. At VH–IVUS
study inclusion 85% of the participants were male; mean (SD)
age was 60.7 (9.7) years, systolic blood pressure 145.7 (20.2)
mmHg, BMI 27.0 (2.9) kg/m2 and ejection fraction 63.2 (7.2)%.
Diabetes mellitus was present in 11%, hypercholesterolemia in
57% and 21% were current smokers. Statins were used by
98% of the population, while acetylsalicylic acid was taken by
94%.
IVUS-lesion characteristics at the time of VH–IVUS study
inclusion are presented in table 2 and an example VH–IVUS
image in Figure 2. Eight patients (7.8%) were identified with a
VH-TCFA lesion at VH–IVUS study inclusion. Regarding
clinical and biochemical characteristics, only apolipoprotein A1
differed statistically significant between the TCFA and non-
TCFA group (p-value 0.05) when not adjusted for multiple
comparisons. After the VH–IVUS study inclusion the 105
patients were followed for a median (IQR) of 734 (112) days
until the end of WENBIT.
Blood indices at WENBIT-baseline and VH–IVUS study
inclusion
Serum median (IQR) MCP-1 levels in the VH–IVUS study
group (n=105) at WENBIT-baseline was 77.1 (34.7) and 85.3
(36.6) pg/mL at VH–IVUS study inclusion. Change in mean
serum MCP-1 from WENBIT-baseline to VH–IVUS study
inclusion was not significant (p=0.19). At WENBIT-baseline,
median (IQR) plasma tHcy was 9.5 (3.4) µmol/L, plasma folate
MCP-1 and Presence of TCFA
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10.9 (6.8) nmol/L and cyanocobalamin 321 (135) pmol/L. Folic
acid/vitamin B12 supplementation significantly raised plasma
folate by mean (SE) 63.7 (3.8) nmol/L (p-value <0.0001) and
cobalamin by 191.3 (36.3) pmol/L (p-value <0.001).
Homocysteine was lowered 29.5% with 2.8 (0.4) µmol/L (p-
value <0.0001).
MCP-1 levels according to supplementation with folic
acid/B12
Folic acid supplementation did not result in a statistically
significant difference in MCP-1 levels between the intervention
groups. At WENBIT-baseline, patients receiving folic acid and
vitamin B12 supplementation had geometric mean (SD) serum
MCP-1 levels of 73.9 (1.4) pg/mL versus 81.6 (1.4) pg/mL for
Table 1. Characteristics and Laboratory Findings in All Patients (n=102) at the Time of WENBIT-baseline.
Characteristics B-vitamin treatment  
Demographic characteristics FA/B12±B6 (n=55) Placebo or B6 (n=47) p-value
 Age, years 60.0 (12.5) 61.0 (14.5) 0.86
 Male sex, no. (%) 46 (83.6) 39 (78.7) 0.86
Clinical Characteristics    
 Systolic blood pressure, mmHg 139.0 (29.0) 146.0 (27.5) 0.71
 Body mass index, kg/m2 27.0 (3.0) 27.0 (4.5) 0.41
Cardiovascular Risk Factors, no. (%)
 Peripheral vascular disease 1 (1.8) 2 (4.3) 0.59
 Cerebrovascular disease 3 (5.5) 3 (6.4) 1.00
 Prior myocardial infarction 20 (36.4) 16 (34.0) 0.97
 Prior surgical revascularization 1 (1.8) 1 (2.1) 1.00
 Hypercholesterolemia* 27 (50.0) 29 (65.9) 0.17
 Hypertension** 22 (40.0) 19 (40.4) 0.87
 Diabetes mellitus I or II 6 (10.9) 5 (10.6) 0.78
 Current smoker 12 (21.8) 9 (19.1) 0.93
 Family history*** 20 (36.4) 17 (36.2) 0.85
Medications, n (%)
 Statins*** 55 (100.0) 46 (96.9) 0.94
 β-adrenergic receptor antagonists 41 (74.5) 32 (66.0) 0.62
 Calcium antagonists 9 (16.4) 8 (17.0) 0.86
 ACE-inhibitors or ARB 18 (32.7) 15 (31.9) 0.90
 Acetylsalicylic acid 51 (92.7) 43 (91.5) 1.00
 ADP receptor antagonists 11 (20.0) 6 (14.6) 0.48
Laboratory Findings, mean (SD)
 C-reactive protein, g/dL 1.06 (2.02) 1.22 (2.18) 0.81
 Hemoglobin, g/dL 14.5 (1.4) 14.1 (1.3) 0.09
 Glucose, mmol/L 6.0 (1.5) 6.0 (1.5) 0.69
 Creatinine, µmol/L 79 (15) 79 (13.5) 0.31
 Total cholesterol, mmol/L 4.3 (1.1) 4.2 (1.0) 0.86
 High density lipoprotein cholesterol, mmol/L 1.4 (0.4) 1.3 (0.4) 0.51
 Low density lipoprotein cholesterol, mmol/L 2.6 (1.0) 2.5 (0.8) 0.78
 Triglycerides, mmol/L 1.37 (0.73) 1.50 (0.59) 0.22
 Apolipoprotein B-100, g/L 0.76 (0.26) 0.75 (0.18) 0.99
 Apolipoprotein A-1, g/L 1.40 (0.23) 1.34 (0.30) 0.42
 Total plasma homocysteine, µmol/L 9.97 (3.83) 9.19 (3.21) 0.17
 Serum folate, nmol/L 11.0 (6.6) 10.2 (7.8) 0.95
 S-cyanocobalamin, pmol/L 316.2 (132.0) 326.6 (136.1) 0.24
 Monocyte chemoattractant protein-1, p g/mL 71.5 (36.8) 82.2 (30.2) 0.17
For continuous variables, median and interquartile range is presented. For categorical variables, number and percentage is presented. FA, folic acid 0.8 mg; B12, vitamin
B12 0.4 mg; B6, vitamin B6 40 mg; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; ADP, adenosine diphosphate; LDL, low-density lipoprotein;
HDL, high-density lipoprotein. Comparison between groups was done with Wilcoxon rank sum test for continuous data and Pearson’s Chi squared test or Fisher’s exact test
were appropriate for categorical data. A p-value of < 0.05 was defined as significant.
*. Defined as a history of untreated total serum cholesterol > 6.5 mmol/L or familial hypercholesterolemia. 4 patients with missing data.
**. Defined as systolic blood pressure > 140 and/or diastolic > 90 mmHg and/or antihypertensive therapy.
***. Family history of coronary artery disease in first degree male relative before the age of 55 and before 65 in first degree female relatives.
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patients given placebo (p-value = 0.15). At VH–IVUS study
inclusion patients with folic acid/vitamin B12 supplementation
had a geometric mean (SD) MCP-1 level of 80.0 (1.5) versus
86.0 (1.4) pg/mL for patients receiving placebo (p-value 0.34)
as illustrated in Figure 3. Multivariate GAM gave similar non-
significant effects on MCP-1 concentration at both WENBIT-
baseline and VH–IVUS study inclusion.
VH–IVUS analyses
A total of 151 coronary vessels from the n=102 patients were
analyzed yielding n=167 coronary IVUS-lesions. Analyzed
coronary vessels in the 102 patients is shown in table 2 and
were n=1 left main stem (0.7%), n=68 left anterior descending
artery (45.0%), n=42 left circumflex artery (27.8%) and n=40
right coronary artery (26.5%). Total plaque volumes in the
analyzed segments were dominated by fibrous histology. At the
lesion level, fibrous histology constituted a relative volume of
58% in non-VH-TCFA lesions and 61% in VH-TCFA lesions,
similarly fibro-fatty constituted 21% and 20%, necrotic volume
13% and 13% while calcified volume made up 8% and 6%. The
mean IVUS-lesion length did not differ significantly between
non-VH-TCFA lesions (43.7 mm) and VH-TCFA lesions (54.4
mm). A VH-TCFA lesion was identified in 7.8% of the patients.
VH-TCFA lesions had significantly higher absolute volumes of
both fibrous, fibrolipidic and necrotic tissue than non-VH-TCFA
lesions (all p-value <0.05). The volume of calcified tissue did
Table 2. Intravascular Ultrasound Derived Virtual Histology
characteristics (n=102).
Variable
Non-VH-TCFA
(n=94) VH-TCFA (n=8) P-value
Fibrous volume,
mm3 70.5 (45.6) 131.7 (51.5) < 0.01
Fibrolipidic
volume, mm3 26.6 (24.1) 47.0 (29.6) 0.03
Necrotic core
volume, mm3 15.9 (14.3) 29.1 (19.9) 0.02
Calcified volume,
mm3 9.0 (6.6) 13.2 (8.2) 0.09
Relative fibrous
volume, % 58 (7) 61 (7) 0.41
Relative
fibrolipidic volume,
%
21 (9) 20 (6) 0.81
Relative necrotic
core volume, % 13 (7) 13 (6) 0.91
Relative calcified
volume, % 8 (6) 6 (3) 0.70
Lesion length, mm 43.7 (18.6) 54.4 (16.8) 0.15
Categorical variables are presented as number and percentage. Absolute volume
measurements are presented as mean (SD) mm3 while relative volume
measurements are presented as percentage (SD). Comparison between groups
were done using Wilcoxon rank sum test. A significance level of 0.05 was used.
VH-TCFA, virtual histology-thin cap fibroatheroma.
not significantly differ between VH-TCFA lesion and non-VH-
TCFA lesions (table 2).
VH-TCFA presence, MCP-1 levels and folic acid
supplementation
The difference in MCP-1 between VH-TCFA and non-VH-
TCFA patients at VH–IVUS inclusion is shown in Figure 4
(n=102). Patients presenting with VH-TCFA lesions had a
geometric mean (SD) MCP-1 level of 117.5 (1.5) versus 80.3
(1.4) pg/mL in the non-VH-TCFA patients. MCP-1 levels were
1.46 (95% CI 1.12–1.92) times higher in patients with VH-
TCFA than those without (p-value 0.006). This was unaffected
by multivariate adjustment (p-value 0.0006).
There was no statistical significant effect of folic acid/vitamin
B12 treatment on the presence of VH-TCFA lesions (p-value
0.47).
Clinical end-points
A statistically significant higher proportion of patients in the
VH-TCFA group experienced an MI during the 2.1 years of
follow-up between VH–IVUS study inclusion and WENBIT end-
of-study visit compared to those without a VH-TCFA lesion
(data not shown).
Patients with an MI during follow-up had 1.6 (95% CI 1.1 to
2.4) times higher levels of MCP-1 at VH–IVUS study inclusion
than event-free patients (p-value 0.01), unaltered by
multivariate adjustment (p-value 0.03). In a Cox proportional
hazard model with MCP-1 levels at VH–IVUS study inclusion,
hazard ratio (HR) [95% CI] for MI increased with 2.1 [0.6 to
3.6]% per pg/mL MCP-1 (p-value 0.006). In multivariate
analysis the HR [95% CI] for MI for MCP-1 was 3.6 [0.5 to
6.8]% per pg/mL increase (p-value 0.02).
Discussion
Principal findings
In patients with CAD receiving established medical treatment
and revascularization with PCI, we found no statistically
significant association between treatment with folic acid/vitamin
B12 and either levels of MCP-1 or the presence of occult VH-
TCFA lesions by IVUS. We did however find a strong,
statistically significant relationship between VH-TCFA lesions
and elevated serum levels of MCP-1. Additionally, in a post-hoc
analysis, MCP-1 levels predicted time to MI in a Cox
proportional hazard model with and without adjustment for
established risk factors.
MCP-1 levels and VH-TCFA presence according to folic
acid/vitamin B12 treatment
While previous studies have found both an association
between plasma tHcy and MCP-1 [16,33] as well as an MCP-1
lowering effect of folic acid supplementation [15,16], we were
unable to reproduce these results in this cohort of patients with
SAP receiving established medical therapy. While others have
reported a correlation of 0.31 between tHcy and MCP-1 [33],
this was not apparent amongst our patients (spearman 0.006),
an observation that is corroborated by no effect of B-vitamin
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treatment on the presence of VH-TCFA lesions. These
apparent discrepancies between results obtained by us and
others [15,16] may reflect different study design and subjects
characteristics, including low tHcy at WENBIT-baseline (<10
µmol/L), the presence of established CAD and statin treatment
in our study population. Notably, it has been shown that in the
presence of obesity and insulin resistance, the correlation
between MCP-1 and tHcy is abolished [17]. Stratifying
according to BMI did however not result in significant effects of
folic acid/vitamin B12 treatment on MCP-1 levels in our study
(data not shown).
MCP-1 and plaque vulnerability
MCP-1/CCL2 is associated with coronary risk factors in sub-
clinical atherosclerosis [34] and is a predictor of cardiovascular
mortality in middle-aged obese patients [35]. Interestingly,
MCP-1 has shown to independently predict clinical end-points
in acute coronary syndromes (ACS) both in the acute [36,37]
and chronic phase [37,38]. We confirmed the correlation
between MCP-1 and coronary events, suggesting that this
effect could be mediated through the presence of vulnerable
plaques represented by VH-TCFA lesions.
Data suggest that TCFA-lesions are present in as much as
two-thirds of culprit lesions [39-41]. Monocyte infiltration is a
prerequisite for the development of atherosclerotic lesions, and
MCP-1 plays an essential role [11-13]. MCP-1 levels and
mRNA expression have recently been associated with acute
coronary syndrome and plaque rupture [42]. We found that
MCP-1 was correlated to VH-TCFA lesions and independently
predicted MI, and 25% of patients in our study with VH-TCFA
experienced a coronary event within 2 years.
MCP-1 is instrumental to the recruitment of monocytes from
the bloodstream into atherosclerotic plaques [10]. In basic
research, MCP-1 has been linked to macrophage activity in
atherosclerotic plaques [11,12], a sine qua non of plaque
destabilization [43,44]. Raised circulating levels of MCP-1
might represent increased monocyte recruitment, a necessary
step on the ladder towards plaque rupture.
Study limitations
There are a few study limitations to be addressed. Most
important is the limited number of patients in the present study.
Performing survival analysis on such data was done as post-
hoc analyses and should be viewed as purely hypothesis-
generating. The ability to independently predict both future MI
and the anatomical substrate for that event is, however,
intriguing and warranted reporting. Furthermore, the statistical
models are fairly robust in spite of low number of events and
Figure 2.  Grayscale IVUS and Virtual Histology of TCFA.  A thin cap fibroatheroma (asterisk) in the proximal left anterior
descending coronary artery of one of the study patients. The left panel shows an intravascular ultrasound radiofrequency image
which is subsequently used to make the virtual histology image in the right panel. Green is fibrous tissue, yellow is fibro-fatty, red is
necrotic core and white is calcified tissue.
doi: 10.1371/journal.pone.0070101.g002
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were not attenuated by multivariate adjustment. A second
limitation is that our patients had a relatively low-number of VH-
TCFA lesions. This could possibly reflect that the patient cohort
was well-treated and clinically stable. A “true” SAP-cohort is
however the sub-group of interest, since this is the patient
group where improved risk prediction would be interesting.
Additionally, all of our patients had undergone PCI, rendering
at least one coronary segment per patient unavailable for VH-
TCFA evaluation, since we would have been unable to discern
whether plaque instability was a result from mechanical stress
due to adjacent stent deployment or inflammatory activity.
Another problem with IVUS-measurements is the size of the
coronary catheter, restricting analyses to proximally located
lesions of large epicardially located arteries. However, a
majority of ruptured plaques and TCFAs were located within
the proximal segments of the left anterior descending artery
and left circumflex artery in patients with cardiac death [45].
Lastly, the relatively low levels of tHcy (<10 µmol/L at baseline
Figure 3.  MCP-1 Levels According to Folic Acid Supplementation at VH–IVUS Study Inclusion.  Cumulative distribution
frequency plots showing plasma Monocyte Chemotactic Protein-1 (MCP-1) on the x-axis in patients receiving folic acid/vitamin B12
(solid line) and placebo or B6 (dashed line).
doi: 10.1371/journal.pone.0070101.g003
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may have masked any anti-inflammatory effect of folic acid/
vitamin B12 treatment.
Study strengths
The study’s main strength is our ability to simultaneously
evaluate the effect of the folic acid/vitamin B12 treatment on
both biochemical and anatomical substrate of coronary
atherosclerosis. In addition, we were able, albeit in post-hoc
analyses, to demonstrate a relationship between a biomarker,
the putative anatomical substrate of disease and clinical end-
points. This contextualizes the MCP-1/VH-TCFA-association.
Figure 4.  MCP-1 and Presence of Occult Thin-Cap Fibroatheroma at VH–IVUS Study Inclusion.  Cumulative distribution
frequency plots of Monocyte Chemotactic Protein-1 (MCP-1) in patients with (solid line) and without (dashed line) Virtual Histology
Thin-Cap Fibroatheroma (VH-TCFA).
doi: 10.1371/journal.pone.0070101.g004
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Conclusions
In this prospective study on patients with established CAD,
folic acid/vitamin B12 supplementation did not alter either
MCP-1 levels or the presence of occult VH-TCFA coronary
lesions in SAP patients. However, MCP-1 was associated with
the presence of VH-TCFA lesions. In post-hoc analyses both
MCP-1 and VH-TCFA independently predicted MI, possibly
reflecting sustained monocytic infiltration and activity in
proximally located, occult thin-cap fibroatheromas not
attenuated by moderate to aggressive pharmacological
treatment. This suggests that plasma levels of MCP-1 could be
used to select SAP patients for further investigations, including
VH–IVUS, to identify patients with VH-TCFA lesions. Further
studies should aim to confirm the association between
vulnerable plaques and levels of MCP-1 and whether MCP-1
measurement could identify patients with VH-TCFA in a
prospective manner.
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